Biomarker analysis of the phase III IMblaze370 trial of atezolizumab plus cobimetinib or atezolizumab monotherapy vs regorafenib in third-line CRCG. Argiles, J. Bendell,T. Kim,M. Wongchenko, K. DuPree, S. Mahrus, X. Qu, Y. Shi, A. Uyei,L. Roberts,Y. Yan,F. CiardielloANNALS OF ONCOLOGY（2020）引用 1|浏览33暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
